First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors
In this large cohort of patients with rare tumors receiving checkpoint inhibitor therapy, grade of immune-related adverse event in the first cycle was predictive for survival.
Authors
- Elad Sharon (ORCID: https://orcid.org/0000-0002-0044-9719)
- Megan Othus (ORCID: https://orcid.org/0000-0001-8176-6371)
- Razelle Kurzrock (ORCID: https://orcid.org/0000-0003-4110-1214)
- Eliana Dietrich (ORCID: https://orcid.org/0009-0000-8836-0374)
- Sandip Pravin Patel (ORCID: https://orcid.org/0000-0002-8387-4840)
- Young Kwang Chae (ORCID: https://orcid.org/0000-0003-1557-7235)
- HOWARD Z. STREICHER (ORCID: https://orcid.org/0000-0003-3683-9804)
Institutions
- Northwestern University (US)
- National Institutes of Health (US)
- Medical College of Wisconsin (US)
- University of California San Diego (US)
- Fred Hutch Cancer Center (US)
- National Cancer Institute (MY)
- Dana-Farber/Harvard Cancer Center (US)
- National Cancer Institute (US)
- SWOG Cancer Research Network (US)
Publication Details
- Journal
- JNCI Journal of the National Cancer Institute
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1093/jnci/djae297
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Bristol-Myers Squibb
- National Institutes of Health
- National Cancer Institute